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Abstract
Background: Rhesus monkey TRIM5a (TRIM5arh) recognizes the incoming HIV-1 core through its C-terminal B30.2(PRYSPRY)
domain and promotes its premature disassembly or degradation before reverse transcription. Previously, we have shown that
TRIM5arh blocks HIV-1 production through the N-terminal RBCC domain by the recognition of Gag polyproteins. Although all
TRIM family proteins have RBCC domains, it remains elusive whether they possess similar late-restriction activities.
Methodology/Principal Findings: We examined the antiviral spectra of TRIM5a orthologues and human TRIM family
memberswhich havea genetic locus proximalto human TRIM5a (TRIM5ahu), against primate lentiviral production. When HIV-
1 virus-likeparticles (VLPs) were generated in the presence of TRIM5a proteins, rhesus, African green and cynomolgus monkey
TRIM5a (TRIM5aag and TRIM5acy), but not TRIM5ahu, were efficiently incorporated into VLPs, suggesting an interaction
between HIV-1 Gag and TRIM5a proteins. TRIM5arh potently restricted the viral production of HIV-1 groups M and O and HIV-
2, but not simian lentiviruses including SIVMAC1A11, SIVAGMTan-1 or SIVAGMSAB-1. TRIM5ahu did not show notable late
restriction activities against these lentiviruses. TRIM5aag and TRIM5acy showed intermediate restriction phenotypes against
HIV-1 and HIV-2, but showed no restriction activity against SIV production. A series of chimeric TRIM5a constructs indicated
that the N-terminal region of TRIM5aag and TRIM5acy are essential for the late restriction activity, while the C-terminal region
of TRIM5acy negatively regulates the late restriction activity against HIV-1. When select human TRIM family proteins were
examined, TRIM21 and 22 were efficiently incorporated into HIV-1 VLPs, while only TRIM22 reduced HIV-1 titers up to 5-fold.
Theantiviral activities and encapsidationefficienciesdidnot correlatewiththeir relative expression levelsinthe producer cells.
Conclusions/Significance: Our results demonstrated the variations in the late restriction activities among closely related
TRIM5a orthologues and a subset of human TRIM family proteins, providing further insights into the late restriction activities
of TRIM proteins.
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Introduction
Approximately 8% of the human genome is comprised of
retroviral elements, implicating an extensive history of competition
between hosts and retroviruses [1,2]. To counteract these viruses,
primates have developed defensive measures which target various
aspects of the retroviral life cycle. Cellular restriction factor
TRIM5a is one such contributing element in this antiviral defense
against retroviruses [3,4,5,6]. TRIM5a belongs to the TRIM
family of proteins, which are characterized by sequential domains
in the N-terminal half of the protein, RING, with one or two b-
boxes followed by a coiled-coil motif and its a isoform includes a
C-terminal B30.2(PRYSPRY) domain. The rhesus monkey
TRIM5a (TRIM5arh) recognizes the incoming HIV-1 core
through its C-terminal B30.2(PRYSPRY) domain and promotes
its premature disassembly or degradation before reverse transcrip-
tion [7,8,9,10]. Primate TRIM5a orthologues have distinct post-
entry restriction activities against a range of retro- and lentiviruses;
however, they generally lack strong restriction activity against their
own host-specific viruses. For instance, human TRIM5a (TRI-
M5ahu) restricts N-tropic murine leukemia virus (N-MLV) as well
as equine infectious anemia virus (EIAV), but not human
immunodeficiency virus type-1 (HIV-1) or simian immunodefi-
ciency virus (SIV) [3,4,6,11]. In contrast, TRIM5arh expression in
HIV-1-permissive cells confers strong antiviral activity against
HIV-1, EIAV, N-MLV and SIV from African green monkeys
(SIVAGM), but not against SIV from rhesus macaques (SIVMAC)
[3,4,6,9,11,12]. The African green monkey TRIM5a orthologue
(TRIM5aag) restricts HIV-1, SIVMAC, EIAV and N-MLV, but
not SIVAGM [3,11], while the cynomolgus monkey orthologue
(TRIM5acy) restricts HIV-1 and HIV-2, but not SIVMAC
infection [13]. These post-entry restriction patterns of TRIM5a
orthologues suggest that lentiviruses have evolved to evade
TRIM5a-mediated post-entry restriction when colonizing respec-
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their TRIM5a proteins, especially the coiled-coil and
B30.2(PRYSPRY) domains, against retro- and lentiviruses [14,15].
TRIM5arh also exhibits an additional antiviral activity against
HIV-1 production, independently of the well-characterized post-
entry restriction, to block the late phase of HIV-1 replication
[16,17]. High levels of TRIM5arh expression blocks HIV-1
production predominantly by reducing the number of HIV-1
virions, while modest TRIM5arh expression blocks the late phase
of HIV-1 replication by reducing virion infectivity as well as virion
numbers [16,18]. When HIV-1 virus-like-particles (VLPs) are
produced in the presence of TRIM5arh, TRIM5arh is efficiently
incorporated into VLPs, implicating the interaction between
cellular and viral components during viral assembly [16]. This
TRIM5arh-mediated restriction of HIV-1 production is mediated
by the N-terminal RBCC domain, but not the C-terminal
B30.2(PRYSPRY) domain [16]. Further studies have identified
several determinants for this late restriction. A RING structure is
essential for the efficient interaction with HIV-1 Gag, while two
amino acid residues in TRIM5arh coiled-coil domain (M133 and
T146) are critical for the late restriction activity [19]. Our data
suggest that the TRIM5arh-mediated late restriction involves at
least two distinct activities: (i) interaction with HIV-1 Gag
polyprotein through the N-terminal, RING and b-box 2 regions
of a TRIM5arh monomer, and (ii) an effector function(s) that
depends upon the coiled-coil and linker 2 domains of TRIM5arh
[19]. Although TRIM5ahu does not show strong late restriction
activities against HIV-1 group M viruses [16], it remains to be
determined if the human orthologue has any late restriction
activity against other human and non-human primate lentiviruses.
Previous studies have shown that TRIM5a is interferon-
responsive [20,21]. Recent study identified TRIM6, 21, 22 and
34, which are located on chromosome 11p together with TRIM5,
are also interferon responsive [22]. Given that the late restriction
of TRIM5a is dependent on the RBCC domain and these TRIM
family proteins possess an N-terminal RBCC, it is possible that
TRIM5ahu paralogues may have similar late-restriction activities.
In the present study, we determined the antiviral spectra and
Figure 1. Amino acid sequence alignment of TRIM5a orthologues examined in this study. Consensus amino acid sequences of TRIM5a.a s
well as TRIM5ahu (Hu), TRIM5arh (Rh), TRIM5aag (Ag) and TRIM5acy (Cy) amino acid sequences are shown. Identical residues are indicated by dots.
Gaps are indicated by dashes. HindIII site in the coiled-coil domain was used as the junction for the chimeras used in this study.
doi:10.1371/journal.pone.0016121.g001
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We found that TRIM5a orthologues from African green
(TRIM5aag) and cynomolgus (TRIM5acy) monkeys have similar,
but weaker late restriction activities against HIV-1 production.
Similar to TRIM5arh, TRIM5aag and TRIM5acy proteins were
efficiently incorporated in HIV-1 VLPs, and their RBCC domains
were essential for the late restriction activities. Intriguingly, the C-
terminal regions of TRIM5aag and TRIM5acy proteins nega-
tively regulated the late restriction activities. Studies using human
TRIM5 paralogues with conserved RBCC domains demonstrated
that TRIM21 and TRIM22 specifically incorporated into HIV-1
VLPs, while only TRIM22 mildly restricted HIV-1 production.
Our results therefore demonstrate the variable late restriction
activities of TRIM5a orthologues and paralogues. The involve-
ment of the C-terminal sequences of TRIM5a proteins in
determining the potency of late restriction activities suggests more
complex mechanisms underlying TRIM protein-mediated late
restriction activities than previously reported.
Methods
Cell culture
293T and GHOST(3)R3/X4/R5 [23] cells were maintained in
Dulbecco’s Modified Eagle’s Medium with 4.5 g/L glucose,
supplemented with 10% fetal bovine serum (FBS) and antibiotics.
Plasmids
TRIM5arh- or TRIM5ahu-expressing plasmids with a C-
terminal HA tag, pRhT5a and pHuT5a, respectively, and codon-
optimized HIV-1 GagPol expression construct pH-G/P were
described previously [16]. pcDNA3.1-based TRIM5aag expres-
sion plasmid (pAgmT5a) was generated from pDON-aT5 [18]
and TRIM5acy cDNA was amplified from total RNA isolated
from cynomolgus monkey lymphoid line, HSC-F cells (kindly
provided by Dr. Hirofumi Akari) and cloned into pcDNA3.1 to
generate pCynT5a. Proviral lentivirus plasmids pNL4-3, p89.6,
p94UG114.1, pSIVmac1A11, pSIVagmTan-1 and pSAB-1 were
obtained from the NIH AIDS Research and Reference Reagent
Program [24,25,26,27,28,29,30,31]. pROD10 was described
previously [32]. pCMO2.41 and pCMO2.5 were generously
provided by Dr. Hans-Georg Kra ¨usslich. Chimeric TRIM5a-
expression plasmids were generated using the conserved HindIII
sites in the coiled coil domain of TRIM5a sequences, and cloned
into pcDNA3.1. N-terminally tagged TRIM1, 6, 18, 21, 22 and 34
were kindly provided by Dr. Paul Bieniasz [33]. Since modifica-
tions in the N-terminal region of TRIM5arh ablated its late
restriction activity [16], we generated C-terminally HA-tagged
human TRIM expression plasmids based on pcDNA3.1(+)
(Invitrogen) and verified their sequences. TRIM5arh point
mutants were generated using the QuikChange II XL site-directed
mutagenesis kit (Stratagene, Cedar Creek, TX).
Figure 2. TRIM5a orthologue expression in 293T cells and antiviral spectrum of TRIM5a orthologues against lentiviral production.
(A) Verification of the proper expression of TRIM5a orthologues. Control plasmid (2), TRIM5ahu (Hu), TRIM5arh (Rh), TRIM5aag (Ag) and TRIM5acy
(Cy) expression in transfected 293T cells were verified via immunoblot analysis. Arrow depicts approximate TRIM5a band size. (B) 293T cells were co-
transfected with a primate lentivirus proviral plasmid and increasing amounts of human (Hu), rhesus monkey (Rh), African green monkey (Ag) or
cynomolgus monkey (Cy) TRIM5a-expressing plasmids. As infectious proviral plasmids, HIV-1 Group M (pNL4-3 and p89.6), HIV-1 Group O (pCMO2.41,
pCMO2.5), HIV-2 (pROD10), and SIV (pSIVMAC1A11, pSIVAGMTan-1 and pSIVAGMSAB-1) were used. Viral titers were determined in GHOST(3)R3X4R5
indicator cells and described as infectious units per ml (IU/ml). Error bars indicate one standard deviation.
doi:10.1371/journal.pone.0016121.g002
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293T cells were transfected with 1.0 mg TRIM5a-expression
plasmid using FuGene 6 (Roche, Madison, WI) in a 6-well culture
plate. 6-h post-transfection, 293T cells were seeded into LabTek II
8-well chamber slides (Nunc, Rochester, NY) at approximately
1.5610
5 cells/ml. 36 h post-transfection, cells were fixed in 4%
paraformaldehyde, permeabilized on ice using 0.1% saponin after
fixation then blocked with 5% FBS PBS solution for 30 min at
room temperature. Primary antibody (rat anti-HA, 1:250, Roche)
and secondary antibody (FITC-conjugated goat anti-rat IgG,
1:250, Thermo Scientific, Waltham, MA) were used to visualize
HA signals. Images were obtained using the Zeiss LSM 510
confocal microscope (Carl Zeiss MicroImaging, Inc., Thornwood,
NY) and analyzed with the Zeiss LSM Image Browser software.
Western Blotting
Proteins were subjected to SDS-PAGE in a 4–15% Tris-HCl gel
and then transferred onto a PVDF membrane at 0.7 mA/cm
2 for
40 min. Membranes were blocked in 5% milk PBS overnight prior
to application of antibodies. Antibodies were used in the following
concentrations: rat anti-HA (1:1000, Roche), and mouse anti-b-
actin (1:1000). HIV-1 Gag proteins were detected using a mixture
of anti-p24 antibodies (183-H12-5C, 1:1000 and AG3.0, 1:500)
[34,35]. Peroxidase-conjugated secondary antibodies (goat anti-rat
IgG and goat anti-mouse IgG, Thermo Scientific) were used at a
1:2000 concentration.
Virus-like-particle incorporation assay
1.0 mg of TRIM5a- or TRIM-expressing plasmid and 0.2 mgo f
a codon-optimized HIV-1 Gag-Pol expression plasmid, pH-GP
[36], were co-transfected into 293T cells using FuGene 6. Two
days post-transfection, transfected cells were harvested in RIPA
buffer to assess TRIM5a and HIV-1 GagPol expression. Culture
supernatants were also harvested, and passed through a 0.45 mm-
pore syringe filter for VLP purification. The filtered supernatants
were then centrifuged at 18,0006g for 90 min through a 20%
sucrose cushion, resuspended in PBS and centrifuged at 18,0006g
for 90 min. Pelleted VLPs were lysed in 5 ml of RIPA buffer and to
which 5 ml of sample buffer was added, heat-denatured and
subjected to immunoblot analysis.
Viral production assay
For the assessment of TRIM5a orthologue antiviral activities,
increasing amounts of pHuT5a, pRhT5a, pAgmT5a and
pCynT5a (0.1, 0.3 and 1.0 mg) were co-transfected with 0.1 mg
of infectious lentiviral proviral plasmid into 293T cells (1.0610
6
cells) using FuGene 6 (Roche). A control plasmid (pBlueScrip-
tIIKS(+), Stratagene) was added to each transfection reaction to
bring the final plasmid concentrations to 1.2 mg per transfection.
Human TRIM family protein antiviral activities were examined
similarly, except 1.0 mg of TRIM-expression plasmid was used in
each reaction. Two days post-transfection, cellular supernatants
were passed through a 0.45 mm-pore syringe filter and the viral
titers in the supernatants were determined as infectious units/ml
(IU/ml) in GHOST(3)R3/X4/R5 indicator cells.
Results
Late restriction activities of TRIM5arh, TRIM5aag and
TRIM5acy against primate lentiviruses
In the well-characterized TRIM5a post-entry restriction, the
TRIM5a B30.2(PRYSPRY) determines the potency and specific-
ity of restriction. In contrast, the late restriction of HIV-1 depends
Figure 3. TRIM5a orthologue incorporation into HIV-1 virus-
like particles and subcellular localization in 293T cells. (A) HIV-1
VLP encapsidation assays using human and simian TRIM5a orthologues.
293T cells were co-transfected with 1.0 mg of TRIM5a-expressing
plasmid and 0.2 mg of a codon-optimized HIV-1 Gag-Pol expression
plasmid (pH-GP). Producer cell proteins and supernatant containing
VLPs were harvested two days post-transfection. Upper panel shows
immunoblot analysis of producer cell lysates probed against TRIM5a
(anti-HA). Lower two panels shows immunoblot analysis of VLPs probed
against TRIM (anti-HA), HIV-1 (anti-p24; 183-5C-H12, 1:1000 and AG3.0,
1:500). Full length (FL), truncated (TR) TRIM5a bands and HIV-1 CA (p24)
are indicated by the arrows. (B–E) 293T cells were transfected with
TRIM5a-expressing plasmid and seeded onto 8-well chamber slides 6h
post-transfection. Cells were fixed with paraformaldehyde and permea-
bilized with 0.1% saponin, then stained against TRIM5aHA tag using rat
anti-HA antibody 3F10 and a FITC conjugated anti-rat IgG secondary
antibody. Representative TRIM5ahu (B), TRIM5arh (C), TRIM5aag (D) and
TRIM5acy (E) images are shown. Bar under the respective images
represent the percentages of cells exhibiting more than three discrete
cytoplasmic bodies (black) or a diffuse signal void of cytoplasmic bodies
(white). Scale bars represent 20 mm.
doi:10.1371/journal.pone.0016121.g003
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RBCC sequences among simian TRIM5a orthologues suggest the
possible late restriction activities in other primate TRIM5a
proteins (Fig. 1). We therefore examined the late-restriction
activities of TRIM5aag and TRIM5acy against a series of human
and non-human primate lentiviruses. Human lentiviruses, HIV-1
group M viruses, HIV-1 group O and HIV-2 viruses were
examined for their sensitivity to TRIM5a-mediated late restric-
tion. HIV-1 group O viruses are divergent from group M viruses
[37] and show different sensitivities to TRIM5arh-mediated Lv1
restriction [38], partly due to their cyclophilin A-independence
[38,39]. Since group O and HIV-2 viruses have been less
successful in colonizing human population than the more-
prevalent HIV-1 group M viruses, we hypothesized that
TRIM5ahu might be able to block the late phase of group O
HIV-1 or HIV-2 replication. SIVMAC and SIVAGM were also
included to test the late restriction activities of TRIM5a proteins
against non-human primate lentiviruses.
Immunoblot analysis was performed to verify the proper
expression of TRIM5aag and TRIM5acy proteins following
transfection into 293T cells (Fig. 2A). TRIM5arh reduced the
titers of two HIV-1 group M clones (NL4-3, 89.6) and HIV-1
group O clones (CMO2.41 and CMO2.5) by up to 60-fold in a
dose-dependent manner (Fig. 2B). TRIM5arh also reduced the
titers of HIV-2 up to 40-fold. Although SIVMAC and SIVAGM
SAB-1 titers were largely unaffected by TRIM5arh, we observed a
10-fold decrease in the titers of SIVAGMTan-1 in the presence of
TRIM5arh (Fig. 2B). TRIM5aag and TRIM5acy showed similar
patterns of late restriction activity to its rhesus monkey orthologue,
although the reductions in viral titers were modest. NL4-3 titers
were reduced by 7-fold in cells expressing TRIM5aag or
TRIM5acy, while 89.6 titers were only reduced by 2-fold.
Although group O isolate CMO2.41 virus titers were reduced
by up to 7-fold when producer cells expressed TRIM5aag or
TRIM5acy, the titers of another Group O clone CMO2.5, which
is based on the CMO2.41 isolate but containing the 59LTR to vpr
sequences from the MVP2171 O-type isolate [40], were strongly
affected by TRIM5aag but not TRIM5acy. TRIM5aag and
TRIM5acy showed little late restriction activity on SIVMAC1A11,
SIVAGMTan-1, SIVAGMSAB-1 and HIV-2 production. Intrigu-
ingly, TRIM5aag reduced SIVAGMTan-1 titers by 6-fold (Fig. 2B),
which may be explained by the difference in the host species of
SIVAGM and TRIM5aag: SIVAGMTan-1 is isolated from the
Chlorocebus tantalus [31] but the TRIM5aag protein used in these
experiments were derived from Chlorocebus aethiops-derived CV1
cells [41]. TRIM5ahu marginally reduced HIV titers, while it did
not affect SIV titers (Fig. 2B).
Efficient encapsidation of rhesus monkey, African green
monkey and cynomolgus monkey TRIM5a into HIV-1
virus-like particles
Previously, we have shown that when HIV-1 proteins were
produced in the presence of TRIM5arh, HIV-1 Gag polyproteins
were rapidly degraded [16]. In contrast, over-expression of codon-
optimized HIV-1 GagPol was able to saturate the late restriction
activity, leading to production of sufficient amounts of VLPs in the
presence of TRIM5arh and efficient incorporation of TRIM5arh
in the VLPs [16,17]. Efficient encapsidation of TRIM5arh into
VLPs generated without HIV-1 protease suggests specific
interaction between TRIM5arh and HIV-1 Gag before or during
HIV-1 assembly [16]. HIV-1 protease appears to cleave
TRIM5arh in the B30.2(PRYSPRY) domain to produce the
truncated, 20 kDa form of TRIM5arh in the VLPs, because
formation of the 20 kDa form was not seen in the VLPs made
without HIV-1 Pol, or in the VLPs treated with HIV-1 protease
inhibitors [16]. TRIM5arh and TRIM5ahu chimeric constructs
demonstrated that processing of TRIM5a proteins was not
necessary for their late restriction activities [16,17]. Since three
simian TRIM5a proteins showed different late restriction activities
(Fig. 2B), we examined the differences in their HIV-1 Gag-
association efficiencies by the VLP encapsidation assay. When
high levels of HIV-1 VLPs were generated in the presence of
TRIM5a proteins, efficient incorporation of truncated forms of
TRIM5arh, TRIM5aag and TRIM5acy, but not TRIM5ahu,
were observed (Fig. 3A). The truncated forms of TRIM5a likely
resulted from the cleavage of TRIM5a proteins in the
B30.2(PRYSPRY) domain by the HIV-1 protease. The efficient
incorporation of the simian TRIM5a proteins into VLPs suggests
a specific interaction between simian TRIM5a proteins and HIV-
1 Gag proteins. Since this experiment was performed under
conditions where the late restriction activities were saturated by
Figure 4. Antiviral activities of chimeric TRIM5a proteins against HIV-1 production. (A) Schematic representation of the chimeric TRIM5a
constructs between human (Hu), rhesus monkey (Rh), African green monkey (Ag) and cynomolgus monkey (Cy) TRIM5a proteins. (B) Upper panel:
late-restriction activities of chimeric TRIM5a proteins upon co-transfection with pNL4-3 into 293T cells. Viral titers were determined in
GHOST(3)R3X4R5 indicator cells and reported as infectious units per ml (IU/ml). Error bars indicate one standard deviation. Lower panel: western blot
analysis of chimeric TRIM5a proteins following transfection into 293T cells. Arrow indicates approximate full-length TRIM5a size.
doi:10.1371/journal.pone.0016121.g004
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TRIM5aag lane (Fig 3A) did not reflect the level of restriction.
Simian TRIM5a orthologues form prominent cytoplasmic
bodies
TRIM5a proteins self-associate to form cytoplasmic bodies,
while dimerization is also required for efficiently binding to
retroviral capsid [42,43]. Immunohistochemistry studies in 293T
cells suggest that TRIM5arh efficiently form cytoplasmic bodies,
while TRIM5ahu primarily displayed more diffused cytoplasmic
localizations [19]. In order to address whether the varying late
restriction activities of three simian TRIM5a proteins were due to
their different subcellular localizations, we determine the localiza-
tions of simian TRIM proteins by immunostaining. 293T cells
were transfected with 1.0 mg of TRIM5a-expressing plasmid.
TRIM5a proteins were then detected with anti-HA antibodies and
analyzed by confocal microscope. TRIM5ahu, which does not
strongly affect HIV-1 production, showed predominantly diffuse
cytoplasmic distribution with little discernible cytoplasmic bodies
(Fig. 3B). In contrast, 59.8%, 52.8% and 52.7% of 293T cells
expressing TRIM5arh, TRIM5aag and TRIM5acy, respectively,
showed discrete cytoplasmic bodies (.3 discrete cytoplasmic body
formations per cell) throughout the cytoplasm (Fig. 3 C–E). Our
data therefore demonstrated similar subcellular localizations of
TRIM5arh, TRIM5aag and TRIM5acy, despite their varying
late restriction activities.
The RBCC sequences of TRIM5aag and TRIM5acy are
essential for the late restriction activity
TRIM5ahu amino acid sequences are the most divergent and
showed the weakest late restriction activity among the tested
TRIM5a orthologues (Fig. 2B). We therefore assessed whether the
substitution with TRIM5ahu N- or C-terminal sequences can
relieve the late restriction activities of the simian TRIM5a
orthologues. Chimeric TRIM5a constructs were generated as
depicted in Figure 4A. Simian TRIM5a proteins with N-terminal
TRIM5ahu sequences showed no effect on HIV-1 (Fig. 4B, upper
panel) or SIVMAC production (data not shown), underscoring the
importance of the RBCC sequences in the late restriction activity
against HIV-1. Although the TRIM5arh-TRIM5ahu chimera,
R/H, showed a late restriction activity as potent as wild-type
TRIM5arh, the two simian TRIM5a chimeras with human N-
terminal sequences, A/H and C/H, showed stronger late
restriction activities than wild-type TRIM5aag and TRIM5acy
(Fig. 4B, upper panel). No prominent differences in protein
expression levels were observed between the chimeric TRIM5a
proteins (Fig. 4B, lower panel). These data indicate that the RBCC
sequences of TRIM5aag and TRIM5acy are essential for the late
restriction activity and suggest the possibility that the C-terminal
regions of simian TRIM5aag and TRIM5acy proteins negatively
regulate TRIM5a late restriction activities against HIV-1.
The influence of variations in the RBCC sequences of
simian TRIM5a proteins on the late restriction activities
Previously, we demonstrated that introduction of two TRI-
M5ahu-specific amino acid residues into TRIM5arh (M133T and
T146A in the coiled-coil region) abrogates the late restriction
activity of TRIM5arh [19]. In the RING, b-box 2 and partial
coiled-coil domains, there are three amino acid differences
between TRIM5arh and TRIM5aag, while only one residue
separates TRIM5arh and TRIM5acy. In order to address the
possible contributions of these residues on the modest late
restriction activities of TRIM5aag and TRIM5acy, we introduced
single amino-acid substitutions into the N-terminal half of
TRIM5arh using corresponding TRIM5aag or TRIM5acy
sequences (Fig. 5A). After verification of similar chimeric TRIM5a
expression levels by immunoblot (Fig. 5B, lower panel), we
examined respective late restriction activities against HIV-1. When
HIV-1 NL4-3 was produced in the presence of TRIM5arh,
TRIM5aag and TRIM5acy, HIV-1 titers were reduced approx-
imately 60-, 7- and 6-folds, respectively, while the TRIM5arh
mutants with single amino acid substitutions, Rh(H29P)Ag,
Rh(K45E)Ag, Rh(G52E)Ag and Rh(M150L)Cy, showed potent
late restriction activities, comparable to that of wild-type
Figure 5. Antiviral activities of TRIM5arh proteins with single-
amino acid substitutions in the RBCC region against HIV-1. (A)
Schematic representation of TRIM5arh constructs carrying single amino
acid residue substitutions. Single residue substitutions corresponding
to TRIM5aag sequences were introduced into C-terminally HA-tagged
TRIM5arh (Rh) to generate Rh(H29P)Ag, Rh(K45E)Ag and Rh(G52E)Ag.
150L TRIM5acy sequence was introduced into TRIM5arh to generate
Rh(M150L)Cy. (B) Upper panel: viral titers of HIV-1 NL4-3 generated in
the presence of TRIM5a proteins carrying single amino acid substitu-
tions. Viral production in the presence of TRIM5arh (RhT5a), TRIM5aag
(AgT5a) and TRIM5acy (CyT5a) are shown for comparison. Viral titers
were determined in GHOST(3)R3X4R5 indicator cells and reported as
infectious units per ml (IU/ml). Error bars indicate one standard
deviation. Lower panel: western blot analysis of single-residue-
substituted TRIM5arh proteins following transfection into 293T cells.
Arrow indicates approximate full-length TRIM5a size.
doi:10.1371/journal.pone.0016121.g005
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variations in the single amino acid residues alone (29P, 45E, 52E
or 150L) cannot explain the modest late restriction activities of
TRIM5acy and TRIM5aag.
C-terminal sequences of TRIM5aag and TRIM5acy
negatively regulates the potency of late restriction
activity
To test whether TRIM5aag or TRIM5acy C-terminal
sequences can impair the late restriction activity against HIV-1,
we generated chimeric TRIM5a constructs as depicted in
Figure 6A. Similar levels of TRIM5a expression were confirmed
via immunoblot (Fig. 6B). Although the restriction activity of the
TRIM5arh protein with N-terminal TRIM5acy sequence
(RhM150LCy) did not notably differ from wild-type TRIM5arh
restriction activities (Fig. 4B), the restriction against HIV-1 was
relieved when C-terminal TRIM5acy sequences were fused with
the N-terminal region of TRIM5arh (Fig. 6C). TRIM5aag C-
terminal sequences in TRIM5arh (R/A) impaired the late
restriction against HIV-1 by 3-fold when compared to wild-type
TRIM5arh (Fig. 6C). These data suggest that C-terminal
sequences of TRIM5a proteins can negatively regulate the late
restriction activities, offering partial explanation to the modest late
restriction activities of TRIM5aag and TRIM5acy against HIV-1.
Encapsidation and late restriction activities of human
TRIM proteins
The 5a isoform of human TRIM protein had very little effect
on HIV-1 production; however TRIM5ahu is one of over 80
members of the RBCC family of TRIM proteins. We therefore
sought to examine whether other human TRIM family proteins
may (1) be incorporated into HIV-1 VLPs and (2) restrict HIV-1
production. From the vast numbers of TRIM family proteins, we
examined TRIM6, TRIM34 and TRIM22 since they are located
in a paralogous cluster which includes TRIM5a [44]. We also
examined the influence of TRIM1, TRIM18 and TRIM21
expression on HIV-1 VLP incorporation. TRIM1 has antiviral
activity against N-tropic murine leukemia virus infection [6] and
TRIM18 is its paralogue. TRIM21 can modulate TRIM5a
ubiquitination [45] as well as the interferon-mediated antiviral
response [46].
To obtain sufficient amounts of VLPs in the presence of TRIM
proteins, we used pH-GP, which generates high levels of HIV-1
GagPol and abrogates the late restriction activities of TRIM5arh
[16]. 293T cells were co-transfected with 1.0 mg of TRIM-
expressing plasmids and 0.25 mg of codon-optimized HIV-1
GagPol-expression plasmid, pH-GP. Cell lysates and HIV-1 VLPs
were harvested as described in materials and methods. Immuno-
blot analysis was performed to detect HA-tagged TRIM proteins
as well as HIV-1 Gag proteins. All TRIM proteins were detected
in the producer cells (Fig. 7A). Efficient VLP incorporation was
evident with TRIM5arh, human TRIM21 and TRIM22 (Fig. 7A).
Previously, we have demonstrated that HIV-1 Gag maturation
delays in the presence of TRIM5a, resulting in accumulation of
premature Gag proteins in producer cells and VLPs [16,17]. This
was also true with human TRIM21 and TRIM22, where VLPs
made in the presence of TRIM21 and TRIM22 showed notable
accumulation of premature Gag proteins, particularly in VLPs
(Fig. 7A). No HA signal was detected in the VLPs made in the
presence of TRIM1, 6 and 34 (Fig. 7A). Intracellular expression
levels of the TRIM proteins were not necessarily correlated with
their incorporation into VLPs, indicating that the incorporation of
TRIM proteins is not due to non-specific packaging of RBCC
proteins into VLPs. These observations suggest the direct or
indirect interaction of TRIM21 and TRIM22 with HIV-1 Gag
proteins in producer cells. No effects on HIV-1 Gag levels in the
presence of TRIM5a or TRIM22 are likely due to the saturation
of late restriction activities by over-expression of codon optimized
HIV-1 Gag.
Next, we examined the correlation between VLP incorporation
status of human TRIM proteins and late restriction activities. To
assess the antiviral activities of these TRIM proteins, 1.0 mgo f
TRIM-expressing plasmids were co-transfected with 0.1 mgo f
pNL4-3, p89.6, pROD10 or pSIVmac1A11 into 293T cells, and
viral titers were determined in GHOST indicator cells. Of the
human TRIM proteins that were assessed, only TRIM22 showed
a slight reduction in NL4-3 and 89.6 titers, while the other TRIM
proteins had no effect (Fig. 7B). None of the human TRIM
proteins showed notable effects on HIV-2 or SIVMAC1A11
production (Fig. 7B).
Discussion
In this report, we examined the late restriction activities and
VLP encapsidation efficiencies of simian TRIM5a orthologues
and related human TRIM proteins, and their late restriction
activities against a panel of lentiviruses. Our results revealed the
Figure 6. The effects of African green and cynomolgus monkey TRIM5a C-terminal sequences on TRIM5arh-mediated HIV-1 late
restriction activities. (A) Schematic representation of the chimeric TRIM5a constructs between rhesus monkey (Rh, filled), African green monkey
(Ag, hatched) and cynomolgus (Cy, dotted) TRIM5a proteins. (B) Western blot analysis of chimeric TRIM5a proteins A/R, R/A and R/C following
transfection into 293T cells. Arrow indicates approximate full-length TRIM5a size. (C) Late-restriction activities of chimeric TRIM5a proteins upon co-
transfection with pNL4-3 into 293T cells. Viral titers were determined in GHOST(3)R3X4R5 indicator cells and reported as infectious units per ml (IU/
ml). Error bars indicate one standard deviation.
doi:10.1371/journal.pone.0016121.g006
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proteins against lentiviral production. The relative expression
levels or subcellular localizations of TRIM5a could not explain the
encapsidation efficiency or the potency of late restriction activity.
The RBCC domains of TRIM5aag and TRIM5acy were essential
for the late restriction, while the C-terminal regions of TRIM5aag
and TRIM5acy negatively regulated the restriction activities.
Similar antiviral spectra between simian TRIM5a orthologues
may suggest a conserved restriction mechanism among these
proteins. Of the examined human TRIM5 paralogues, TRIM21
and TRIM22 were efficiently incorporated into HIV-1 VLP, while
only TRIM22 showed marginal late restriction activity.
Among primate lentiviruses, HIV-2 and SIVMAC are closely
related, as sooty mangabey SIV has transferred to humans and
rhesus monkeys as HIV-2 and SIVMAC [47]. However, TRI-
M5arh blocks the infection of HIV-2, but not SIVMAC, mainly due
to the difference in the structure in the capsid protein that recruits
cyclophilin A into HIV-1 virions [48]. Examination of HIV-2 and
Figure 7. HIV-1 VLP encapsidation and late restriction activities of human TRIM proteins. (A) Immunoblot analyses of C-terminally HA-
tagged human TRIM proteins (1, 5a, 6, 18, 21, 22 and 34) with or without codon-optimized HIV-1 Gag-Pol expression plasmid (pH-G/P) are shown.
TRIM5arh was used as a positive control for incorporation. Top three panels show proteins harvested from producer cell lysates, immunoblotted
against TRIM (anti-HA), HIV-1 (anti-p24; 183-5C-H12, 1:1000 and AG3.0, 1:500) or actin (anti-b-actin), while the bottom two panels show immunoblots
of VLPs harvested from respective producer cells against TRIM (anti-HA) or HIV-1 (anti-p24; 183-5C-H12, 1:1000 and AG3.0, 1:500). FL designates
approximate full-length TRIM size, and p24 designates HIV-1 p24 capsid size. (B) 293T cells were co-transfected with 1.0 mg of TRIM-expressing
plasmid: TRIM5arh, TRIM1, TRIM5ahu, TRIM6, TRIM18, TRIM21, TRIM22 and TRIM34, with 0.1 mg of lentivirus proviral plasmid: pNL4-3, p89.6, pROD10
or pSIVMAC1A11. Viral titers were determined in GHOST(3)R3X4R5 indicator cells and reported as infectious units per ml (IU/ml). Error bars indicate
one standard deviation.
doi:10.1371/journal.pone.0016121.g007
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demonstrated the most remarkable differences between the two
closely related lentiviruses. Although SIVMAC was resistant to all
four TRIM5a orthologues in the late-restriction, up to a 40-fold
reduction in HIV-2 production was observed in the presence of
TRIM5arh. It is possible that the variations in the CA loop
regions of SIVMAC and HIV-2, which correspond to the HIV-1
CA cyclophilin-binding loop, may in part contribute to the
differential late restriction phenotypes. However, the CA loop
region cannot solely explain the resistance of SIVMAC to the
TRIM5arh-mediated late restriction, because an HIV-1 cyclophi-
lin-binding loop mutant with corresponding SIVMAC sequence
was still sensitive to the late restriction [36]. Intriguingly, a recent
study has shown that a single amino acid change in the HIV-1 CA
cyclophilin-binding loop allowed the virus to escape from
TRIM5arh-mediated post-entry restriction, suggesting the impor-
tance of the CA loop structure for restriction factor recognition
[49]. Our previous study has also suggested that SIVMAC resists
TRIM5arh-mediated late restriction by counteracting or saturat-
ing the TRIM5a late restriction machinery, rather than escaping
TRIM5arh recognition altogether [36]. We therefore speculate
that the sensitivity of HIV-2 to TRIM5arh-mediated late
restriction is partly due to the relatively inefficient HIV-2
production from pROD10, where production of progeny virions
may not be sufficient to overcome the TRIM5arh-mediated late
restriction. The different replication kinetics of CMO2.41 and
CMO2.5 in PBMCs can be attributed to the gag-pol region of
CMO2.5, which is derived from a separate primary type-O isolate
[50]. The differences in viral gag-pol sequences offers partial
explanation as to why CMO2.41 and CMO2.5 responded
differently to the late restriction activities of TRIM5aag (Fig. 2B).
The incorporation of TRIM5arh into the VLPs made with
HIV-1 Gag suggests a specific interaction between TRIM5arh
and HIV-1 Gag polyproteins [16]. Determinants for this
interaction lie in the RING and coiled-coil domains of
TRIM5arh, and the B30.2(PRYSPRY) motif is not required for
the interaction or the late restriction activity of TRIM5arh [19].
TRIM5arh mutants with the M133T and/or T146A amino acid
substitutions in TRIM5arh coiled-coil domain showed efficient
encapsidation but impaired late restriction activity [19]. Although
the RBCC sequences, including the M133 and T146, of three
simian TRIM5a proteins are highly conserved among the three
simian TRIM5a proteins, we found that TRIM5aag and
TRIM5acy showed weaker late restriction activities than TRI-
M5arh. Similar to our previous study, replacement of the N-
terminal RBCC sequences of TRIM5aag and TRIM5acy with the
corresponding TRIM5ahu sequences resulted in the loss of
prominent late restriction effects of these two simian TRIM5a
proteins, indicating the essential roles of the RBCC domains in
their late restriction activities (Fig. 4B). Unexpectedly, C-terminal
TRIM5ahu sequences mildly strengthened the late restriction
activities of TRIM5aag and TRIM5acy; while impaired late
restriction activities were observed when the N-terminal region of
TRIM5arh was fused with C-terminal TRIM5aag or TRIM5acy
sequences (Fig. 6C). These results indicate that TRIM5a RBCC
sequences are required for the late restriction, and C-terminal
amino acid sequences can modulate the potency of the late
restriction against HIV-1, adding further complexity to the
mechanisms of TRIM5a-mediated late restriction. Further studies
will determine the extent of inter-domain communication within
the TRIM5a protein and the amino acid residues which are
responsible for the negative regulation.
Proteins that have a conserved RING, b-box 1 and/or b-box 2
and coiled-coil domains are included in the superfamily of TRIM
genes, and many TRIM proteins have been implicated to be
interferon-responsive and a contributing factor in the defense
against infectious agents [42,51]. Located in the same genetic locus
on chromosome 11p15, TRIM5, TRIM22, TRIM6 and TRIM34
were classified in the same clade [22]. Of the human TRIM
proteins assessed in this study, TRIM21 and TRIM22 were
efficiently incorporated into VLPs. A faint TRIM18 signal was
also detected in the purified VLPs, suggesting weak interaction
between human TRIM18 and HIV-1 Gag (Fig. 7A). In contrast to
the efficient encapsidation of these proteins, only TRIM22 showed
a modest late restriction activity against HIV-1 (Fig. 7B and C).
These data suggest that encapsidation efficiency alone could not
fully explain the differences in the late restriction activities of
TRIM proteins. It is likely that additional determinant(s) controls
the potency of the late restriction activity following initial binding
of a TRIM protein with HIV-1 Gag.
In summary, we demonstrated the examples of TRIM protein-
mediated late restriction activities and their potential to interact
with viral proteins. Our data provide further insights into the
complex host-pathogen interplay in TRIM protein-mediated late
restriction.
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